A carregar...
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are...
Na minha lista:
| Publicado no: | Clin Sarcoma Res |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4552408/ https://ncbi.nlm.nih.gov/pubmed/26322224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-015-0035-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|